JP2008520187A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520187A5 JP2008520187A5 JP2007537962A JP2007537962A JP2008520187A5 JP 2008520187 A5 JP2008520187 A5 JP 2008520187A5 JP 2007537962 A JP2007537962 A JP 2007537962A JP 2007537962 A JP2007537962 A JP 2007537962A JP 2008520187 A5 JP2008520187 A5 JP 2008520187A5
- Authority
- JP
- Japan
- Prior art keywords
- flavivirus
- chimeric
- mutation
- chimeric flavivirus
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62046604P | 2004-10-20 | 2004-10-20 | |
| US60/620,466 | 2004-10-20 | ||
| US62094804P | 2004-10-21 | 2004-10-21 | |
| US60/620,948 | 2004-10-21 | ||
| US67441505P | 2005-04-24 | 2005-04-24 | |
| US60/674,415 | 2005-04-24 | ||
| US67454605P | 2005-04-25 | 2005-04-25 | |
| US60/674,546 | 2005-04-25 | ||
| US71892305P | 2005-09-19 | 2005-09-19 | |
| US60/718,923 | 2005-09-19 | ||
| PCT/US2005/037369 WO2006044857A2 (en) | 2004-10-20 | 2005-10-19 | Vaccines against japanese encephalitis virus and west nile virus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008520187A JP2008520187A (ja) | 2008-06-19 |
| JP2008520187A5 true JP2008520187A5 (https=) | 2011-02-03 |
| JP4993301B2 JP4993301B2 (ja) | 2012-08-08 |
Family
ID=36203650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007537962A Expired - Lifetime JP4993301B2 (ja) | 2004-10-20 | 2005-10-19 | 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8029802B2 (https=) |
| EP (1) | EP1809325B1 (https=) |
| JP (1) | JP4993301B2 (https=) |
| KR (1) | KR101501162B1 (https=) |
| AU (1) | AU2005295438B2 (https=) |
| CA (1) | CA2584228C (https=) |
| EA (1) | EA015907B1 (https=) |
| IL (1) | IL182453A0 (https=) |
| MY (1) | MY148075A (https=) |
| NO (1) | NO20071924L (https=) |
| NZ (1) | NZ584079A (https=) |
| SG (1) | SG156666A1 (https=) |
| WO (1) | WO2006044857A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002102828A2 (en) | 2001-06-01 | 2002-12-27 | Acambis, Inc. | Chimeric flavivirus vectors |
| KR101194818B1 (ko) | 2002-01-15 | 2012-10-25 | 사노피 파스테르 바이오로직스, 엘엘씨 | 플라비바이러스 백신 |
| ATE452900T1 (de) | 2002-11-15 | 2010-01-15 | Sanofi Pasteur Biologics Co | Impfstoff gegen das west-nile-virus |
| JP4993301B2 (ja) | 2004-10-20 | 2012-08-08 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン |
| AU2013204985B2 (en) * | 2005-04-24 | 2016-01-28 | Sanofi Pasteur Biologics, Llc | Recombinant flavivirus vaccines |
| CA2605924A1 (en) | 2005-04-24 | 2006-11-02 | Acambis Inc. | Recombinant flavivirus vaccines |
| SG10202012986SA (en) | 2006-09-29 | 2021-01-28 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formulations |
| CL2007003209A1 (es) | 2006-11-07 | 2008-05-09 | Acambis Inc | Composicion que comprende una vacuna de flavivirus vivos atenuados; composicion que comprende un producto farmaceutico derivado de virus o proteina; un metodo para la elaboracion de una composicion terapeutica que comprende liofilizar las composicion |
| CA2676775A1 (en) * | 2007-01-31 | 2008-09-25 | Sanofi Pasteur Biologics Co. | Flavivirus vaccine vector against influenza virus |
| US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
| JP2010539192A (ja) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ，インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
| US8715689B2 (en) * | 2008-04-30 | 2014-05-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Chimeric west nile/dengue viruses |
| AU2009279456B2 (en) | 2008-08-08 | 2015-02-05 | Takeda Vaccines, Inc. | Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity |
| CN102292345B (zh) * | 2008-11-17 | 2015-12-02 | Vgx药品有限责任公司 | 引起对抗黄病毒的免疫应答的抗原及其应用方法 |
| NZ597000A (en) * | 2009-06-01 | 2014-07-25 | Takeda Vaccines Inc | Compositions and methods for administration of vaccines against dengue virus |
| US8968996B2 (en) | 2009-06-01 | 2015-03-03 | Takeda Vaccines, Inc. | Compositions and methods for rapid immunization against dengue virus |
| CA3150430A1 (en) | 2009-07-31 | 2011-02-03 | Pnuvax Inc. | High yield yellow fever virus strain with increased propagation in cells |
| EP2550292B1 (en) * | 2010-03-24 | 2017-11-22 | Research Development Foundation | Flavivirus host range mutations and uses thereof |
| CN101926989A (zh) * | 2010-06-29 | 2010-12-29 | 西北农林科技大学 | 表达jev免疫原基因的重组减毒鼠伤寒沙门氏菌载体疫苗及其制备方法 |
| WO2012003320A2 (en) * | 2010-07-01 | 2012-01-05 | Research Development Foundation | Flavivirus host-range mutations and uses thereof |
| CA2841356C (en) | 2011-07-11 | 2022-03-01 | Takeda Vaccines, Inc. | Parenteral norovirus vaccine formulations |
| US9267114B2 (en) * | 2012-11-07 | 2016-02-23 | Southern Research Institute | Flavivirus envelope protein mutations affecting virion disassembly |
| JP2016504315A (ja) | 2012-12-14 | 2016-02-12 | タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. | 三価デングウイルス製剤に関する組成物、投与方法および使用 |
| BR112015031226A2 (pt) | 2013-06-21 | 2017-08-29 | Merck Sharp & Dohme | Composição de vacina, e, uso da composição de vacina |
| EP3013852B1 (en) | 2013-06-26 | 2019-06-19 | The University of North Carolina at Chapel Hill | Compositions for dengue virus vaccines and their use |
| WO2016079560A1 (en) | 2014-11-21 | 2016-05-26 | Institut Pasteur | A live and attenuated japanese encephalitis virus comprising a mutated m protein |
| EP3236997B1 (en) | 2014-12-22 | 2024-05-29 | Merck Sharp & Dohme LLC | Dengue virus vaccine compositions and methods of use thereof |
| UA126548C2 (uk) * | 2015-07-16 | 2022-11-02 | Бхарат Біотек Інтернешнл Лімітед | Вакцинна композиція для профілактики абровірусних інфекцій |
| BR112021019241A8 (pt) * | 2019-03-28 | 2022-12-06 | Pasteur Institut | Flavivírus vivos e atenuados, ácidos nucleicos de rna e de cdna, células recombinantes, clones de cdna, composições imunogênicas e vírus do nilo ocidental (wnv) vivo e atenuado |
| EP4724462A1 (en) * | 2023-06-08 | 2026-04-15 | ModernaTX, Inc. | Stabilized flavivirus vaccines |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173418A (en) | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
| US6676936B1 (en) | 1988-07-14 | 2004-01-13 | The United States Of America As Represented By The Department Of Health And Human Services. | Chimeric and/or growth-restricted flaviviruses |
| US6184024B1 (en) | 1988-07-14 | 2001-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric and/or growth-restricted flaviviruses |
| US6962708B1 (en) | 1997-02-28 | 2005-11-08 | Acambis, Inc. | Chimeric flavivirus vaccines |
| HU228705B1 (en) | 1997-02-28 | 2013-05-28 | Univ St Louis | Chimeric flavivirus vaccines |
| US6589533B1 (en) | 1997-09-18 | 2003-07-08 | Research Development Foundation | Genetically-engineered alphaviruses, flaviviruses, and bunyaviruses with modified envelope transmembrane glycoproteins and altered host-range phenotype |
| ATE314476T1 (de) | 1997-10-08 | 2006-01-15 | Us Gov Health & Human Serv | Chimärer impfstoff gegen das zeckenenzephalitis virus |
| US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
| WO2001039802A1 (en) | 1999-12-01 | 2001-06-07 | Oravax, Inc. | Chimeric flavivirus vaccines |
| WO2002081753A1 (en) | 2001-04-04 | 2002-10-17 | Advanced Research & Technology Institute | Method for identifying and characterizing individual dna molecules |
| KR101194818B1 (ko) | 2002-01-15 | 2012-10-25 | 사노피 파스테르 바이오로직스, 엘엘씨 | 플라비바이러스 백신 |
| US20050002968A1 (en) | 2002-01-15 | 2005-01-06 | Monath Thomas P. | Flavivirus vaccines |
| WO2003060088A2 (en) | 2002-01-15 | 2003-07-24 | Acambis, Inc. | Viral vaccine production method |
| ATE452900T1 (de) | 2002-11-15 | 2010-01-15 | Sanofi Pasteur Biologics Co | Impfstoff gegen das west-nile-virus |
| US7189403B2 (en) * | 2003-06-30 | 2007-03-13 | Institut Pasteur | Attenuated flavivirus strains containing a mutated M-ectodomain and their applications |
| JP4993301B2 (ja) | 2004-10-20 | 2012-08-08 | サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー | 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン |
| CA2605924A1 (en) | 2005-04-24 | 2006-11-02 | Acambis Inc. | Recombinant flavivirus vaccines |
-
2005
- 2005-10-19 JP JP2007537962A patent/JP4993301B2/ja not_active Expired - Lifetime
- 2005-10-19 SG SG200906992-3A patent/SG156666A1/en unknown
- 2005-10-19 EP EP05811861.3A patent/EP1809325B1/en not_active Expired - Lifetime
- 2005-10-19 EA EA200700904A patent/EA015907B1/ru not_active IP Right Cessation
- 2005-10-19 WO PCT/US2005/037369 patent/WO2006044857A2/en not_active Ceased
- 2005-10-19 NZ NZ584079A patent/NZ584079A/en not_active IP Right Cessation
- 2005-10-19 AU AU2005295438A patent/AU2005295438B2/en not_active Expired
- 2005-10-19 KR KR1020077011389A patent/KR101501162B1/ko not_active Expired - Lifetime
- 2005-10-19 CA CA2584228A patent/CA2584228C/en not_active Expired - Lifetime
- 2005-10-19 US US11/577,569 patent/US8029802B2/en not_active Expired - Lifetime
- 2005-10-20 MY MYPI20054938A patent/MY148075A/en unknown
-
2007
- 2007-04-11 IL IL182453A patent/IL182453A0/en unknown
- 2007-04-16 NO NO20071924A patent/NO20071924L/no not_active Application Discontinuation
-
2011
- 2011-10-03 US US13/251,424 patent/US8691550B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008520187A5 (https=) | ||
| CA2584228A1 (en) | Vaccines against japanese encephalitis virus and west nile virus | |
| McMinn | The molecular basis of virulence of the encephalitogenic flaviviruses. | |
| Zeng et al. | Identification of specific nucleotide sequences within the conserved 3′-SL in the dengue type 2 virus genome required for replication | |
| Gualano et al. | Identification of a major determinant of mouse neurovirulence of dengue virus type 2 using stably cloned genomic-length cDNA | |
| Xie et al. | Targeting dengue virus NS4B protein for drug discovery | |
| Shi et al. | Infectious cDNA clone of the epidemic West Nile virus from New York City | |
| Fu et al. | Full-length cDNA sequence of dengue type 1 virus (Singapore strain S275/90) | |
| Tilgner et al. | The flavivirus-conserved penta-nucleotide in the 3′ stem-loop of the West Nile virus genome requires a specific sequence and structure for RNA synthesis, but not for viral translation | |
| Qi et al. | Biological characteristics of dengue virus and potential targets for drug design | |
| Pang et al. | Development of Dengue virus type 2 replicons capable of prolonged expression in host cells | |
| Goncalvez et al. | Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein | |
| US8871222B2 (en) | Recombinant Flavivirus vaccines | |
| Hayasaka et al. | Amino acid changes responsible for attenuation of virus neurovirulence in an infectious cDNA clone of the Oshima strain of tick-borne encephalitis virus | |
| Schlick et al. | Helices α2 and α3 of West Nile virus capsid protein are dispensable for assembly of infectious virions | |
| Maloney et al. | Identification of the flavivirus conserved residues in the envelope protein hinge region for the rational design of a candidate West Nile live-attenuated vaccine | |
| Yoshii et al. | Construction of an infectious cDNA clone for Omsk hemorrhagic fever virus, and characterization of mutations in NS2A and NS5 | |
| Liu et al. | Homologous RNA secondary structure duplications in 3′ untranslated region influence subgenomic RNA production and replication of dengue virus | |
| Frimayanti et al. | Fragment-based molecular design of new competitive dengue Den2 Ns2b/Ns3 inhibitors from the components of fingerroot (Boesenbergia rotunda) | |
| Růžek et al. | Virology. Chapter 2a | |
| Kelly et al. | Evolution of attenuating mutations in dengue-2 strain S16803 PDK50 vaccine and comparison of growth kinetics with parent virus | |
| TH64126B (th) | วัคซีนต้านไวรัสไข้สมองอักเสบและเวสต์ไนล์ไวรัส | |
| TH77925A (th) | วัคซีนต้านไวรัสไข้สมองอักเสบและเวสต์ไนล์ไวรัส | |
| Růžek et al. | Chapter 4. TBE virology | |
| Ramos-Lorente et al. | The 3żUTR of the West Nile Virus genomic RNA is a potential antiviral target site |